📣 At Clario we're committed to improving participant choice and accessibility in #clinicaltrials. We are thrilled to announce the addition of Dark Mode to our eCOA platform, offering greater flexibility and comfort for users. This further enhances our current accessibility capabilities, including our Zoom In/Out feature for participants with visual impairment. ➡ Benefits for Participants: 1. Improved Participant Choice: better user experience with the ability to choose between dark mode and light mode 2. Reduce Sensitivity to Light: For individuals prone to conditions like migraines, bright screens can be a significant trigger 3. Enhanced Readability: providing a higher contrast between the text and the background 4. Reduced Eye Strain: Dark mode is designed to be easier on the eyes, particularly in low-light conditions "Not only will this be helpful for patients with light sensitivity, like those with migraine or certain ophthalmic indications, but this is another step forward in bringing patient choice to the forefront of our eCOA designs." Kelly Dumais, PhD, Director, eCOA Science and Consulting. Learn more about our eCOA accessibilities: https://lnkd.in/d3tzKCDp
Clario
Biotechnology Research
Philadelphia, Pennsylvania 97,519 followers
Transforming Lives by Unlocking Better Evidence | Decentralized clinical trials | Broadest endpoint technology
About us
Clario is a leading healthcare research and technology company that generates high quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Since our founding more than 50 years ago, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported clinical trials over 26,000 times in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2019. For more information, visit Clario.com
- Website
-
https://clario.com/
External link for Clario
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Privately Held
- Founded
- 1972
- Specialties
- Cardiac Solutions, Medical Imaging, eCOA, Respiratory Solutions, Precision Motion, Specialty Solutions, Clinical Adjudication, and Artificial Intelligence
Locations
Employees at Clario
Updates
-
For drug sponsors and CROs, accuracy in cardiac safety data is critical. Our ECG Quality Score Tool directly addresses this need, offering enhanced insights into data quality. Powered by a robust AI/ML platform trained on over 80,000 ECG data points, our tool delivers actionable insights – enabling proactive issue resolution and increasing the likelihood of supporting a TQT waiver. With this technology, you can minimize risks, streamline cardiac assessments and push forward with confidence towards successful trial outcomes. ➡️ For more details, see our Quality Score White Paper: https://hubs.li/Q02HDbqt0
-
-
Today is World Brain Day, a day to raise awareness and promote education for neurological disorders around the globe. 🧠 At Clario, we’re proud of the contributions we've made to help our partners advance drug development across neuroscience indications. But there's still more work to do. Discover how Clario can help enhance sensitivity to detect efficacy, accurately characterize a safety profile, and quantify the patient quality of life in your neuroscience trials. ➡️Visit #ClarioNeuroscience: https://hubs.li/Q02Hrc9d0 #WorldBrainDay #WBD2024 #neuroscience #clinicaltrials
-
-
Clario is excited to share that our SVP General Counsel, Lauren Misztal, will speak at the Women Leaders in Life Sciences Law Summit on July 26. She'll join a session titled, "Harnessing Generative AI in Business Operations and Legal Practice." The panel will cover topics including: -How life sciences companies and law firms are using generative AI for legal research, contract drafting, patent analysis, and more. -Ethical considerations of generative AI, such as bias, fairness, and accountability. -Successful integration of generative AI into legal and business practices. ➡️ Don't miss this insightful discussion! Find more information here: https://hubs.li/Q02H5lKp0 American Conference Institute #womeninlaw #womeninscience
-
-
At Clario, we're always looking for the best talent to help us transform lives. That's where our talent acquisition team comes in! Our team in Hungary, Germany, the UK, China, and Japan is on the hunt for job seekers who are committed to making a difference. Is that you? If so, check out Matthew Stedman's post below. 👇
Friday Fun in the EMEA-APAC TA Coffee Club, absolutely love this team and their ongoing achievements in hiring top talent here at Clario 🚀 The team have fantastic career opportunities available in #hungary #germany #uk #china and #japan You can search for your next opportunity with us by jumping over to our careers page: https://lnkd.in/ek8yEP47 Alternatively connect with Nathalie Fischer Sebastian Braun Ágnes Schwarzenberger Tünde Sztojov and introduce yourself to the team 👋🏽 At Clario, we put people first, always. We are united and driven by patients, committed to making a difference, and we are always looking for the best talent, to help us transform lives. #clinicalresearch #clinicaltrials #pharma #biotech #funfriday #talentacquisition #hiring #jobs #careers #technology
-
-
Our EVP & Chief Medical Officer, Todd Rudo, M.D. has been invited to participate in a September webinar hosted by Dr. Vince Clinical Research, "Accelerating Clinical & Drug Development Timelines with AI." He and other industry experts will delve into how AI is transforming clinical project management, revolutionizing research outputs, and speeding up drug discovery. Secure a spot for the webinar now. Use the link in the post below to register ⬇
𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: “Accelerating Clinical & Drug Development Timelines with AI”. 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄! 👉 https://bit.ly/3L8H0MQ Master AI to propel drug development to new levels of efficiency and innovation. Join our upcoming webinar to: ✅ 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 how AI can be used to accelerate drug discovery, setting new benchmarks for the industry. ✅𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗲 AI to expedite downstream data tabulation and analysis to support broader CRO functions. ✅𝗟𝗲𝗮𝗿𝗻 how to responsibly advance the use of AI in clinical trials and bring value to digital endpoint collection. ✅𝗘𝘅𝗽𝗹𝗼𝗿𝗲 real-world applications and best practices for integrating AI into your project management strategy. Dr. Vince Clinical Research | Enveda Biosciences | Clario | Fierce Biotech #ArtificialIntelligence #AI #BioPharma #BioTech #MachineLearning #Technology #DataScience #ComputerScience #Data #DataAnalytics #DVCR #Clario #DrugDevelopment #ClinicalDevelopment
-
-
Attending #AAIC24? Discover the latest Alzheimer’s disease research presented by the Clario science team at this year's AAIC conference. Don't miss this opportunity to get informed and explore groundbreaking findings that could bring new hope in the fight against Alzheimer’s disease. From the latest advancements in imaging techniques, to understanding industry trends in eCOA assessments, there is much to learn! Join the Clario team's poster sessions for the latest in cutting-edge research! Find out more information here: https://hubs.li/Q02GCY9_0 We hope to see you there! Alzheimer's Association®
-
-
The European Union AI Act has just been published! For more insights on this significant development in #AI regulation, check out this post by our Chief AI Officer, Marko Topalovic. ⬇
Chief AI Officer @ Clario | Harnessing artificial intelligence and machine learning to transform clinical trial endpoint analysis and the sponsor experience
It’s official! The European Union AI Act has just been published. It marks a significant development in the regulation of artificial intelligence technologies. This legislation aims to set comprehensive standards for the ethical and responsible deployment of AI, addressing several critical areas. At Clario, we are taking all aspects of #AI very seriously. Compliance with any regulation, including the new AI Act, is of utmost importance to us. We are committed to ensuring all our AI technologies adhere to these standards, fostering a trustworthy and reliable environment for patients and study sponsors. As a reminder, key elements of the AI Act: - Risk-based approach: Obligations for providers and users are laid out depending on the AI system’s level of risk. - Transparency and Accountability: The Act requires clear guidelines to ensure transparency in AI systems, enabling users to understand the basis of AI-driven decisions. - Ethical Considerations: Emphasizes the importance of ethical AI development, focusing on fairness, mitigation of biases, and respect for human rights. - Safety and Security: Robust measures are introduced to manage risks, enhance cybersecurity, and prevent the misuse of AI technologies. The AI Act is a crucial step in ensuring that AI technologies are developed and utilized responsibly. Even though regulation is seen as a bottleneck to innovation, I believe in the opposite. It will help us to safeguard high-quality innovation, especially in sensitive industries such as healthcare and life science where we are involved daily and it will help sustain the credibility and trustworthiness of all upcoming AI breakthroughs. I am looking forward to seeing the collaborative work of all stakeholders across sectors in implementing these guidelines. Special thanks to the amazing team at Clario who is ensuring the right governance of #AI Tancredi Vergani, Lauren Misztal, Todd Rudo, Gaurav Josan and Jay Ferro. How do you see the new Act impacting the future of AI development? https://lnkd.in/e4eWDAxb
-
The integration of efficacy, safety, and quality of life data maximizes the overall value of a clinical trial, enabling an inclusive assessment of benefits and risks, and ensuring that novel cancer therapies meet patients’ needs holistically. That’s the argument made in an article by Clario's Chief Medical Officer, Todd Rudo, M.D.; Chief Science and Regulatory Advisor-Cardiology, Robert B. Kleiman MD, M.D.; and Director of eCOA Science, Kelly Dumais, Ph. D. Check out the article for their guidance on how to design oncology trials for a comprehensive understanding of the therapeutic impact and patient quality of life in the development of new oncology drugs. ➡️ https://hubs.li/Q02GbGmt0 #clinicaltrials #oncology #drugdevelopment
-
-
Last call to register! 📣 Secure your spot today for our webinar: “Revolutionizing Ophthalmology Clinical Trials Through Enhanced Accessibility and Advanced AI-driven Analysis.” Join Clario's experts Todd Rudo, Amit Vasanji, and Kelly Dumais as they explore strategies to enhance patient access and precision analysis using artificial intelligence (AI) in ophthalmology clinical trials. They will delve into vendor-agnostic, multi-modality platforms, AI-enabled workflows, and best practices for eCOA implementation in various trial settings. ➡️ Register here: https://hubs.li/Q02G10d70 #AI #artificialintelligence #clinicaltrials